Ridgeline Discovery
Andrew Jefferson has a strong background in the biotechnology industry, primarily in Chief Operating Officer roles. Andrew has held this position at multiple companies, including Bright Peak Therapeutics AG, Vector BioPharma AG, Ridgeline Discovery, Matterhorn Biosciences AG, Cimeio Therapeutics AG, RedRidge Bio AG, and Granite Bio AG. Andrew is currently serving as a Board Member at Nouscom AG and an Operating Partner at Versant Ventures.
Andrew Jefferson attended the University of Nottingham from 1987 to 1990, where they obtained a BSc (Hons) degree in Chemistry. Andrew later pursued an MBA in Business Administration at the University of Brighton from 1995 to 1999.
This person is not in any offices
Ridgeline Discovery
Ridgeline Discovery, a Versant Ventures Discovery Engine, creates and operates Versant-financed innovative biotech companies in partnership with entrepreneurs, industry and leading academics across Europe. In recent years, Ridgeline has assembled an international team of >50 highly experienced drug discovery professionals and built and operated several new successful companies, including Black Diamond Therapeutics (NASDAQ: BDTX), Bright Peak Therapeutics and Monte Rosa Therapeutics (NASDAQ: GLUE). Ridgeline is currently expanding its capabilities in Basel to support further company creation efforts in small molecules, biologics, and gene/cell therapy with focus on oncology and immunology.